Suven Pharmaceuticals Limited

NSE SUVENPHAR.NS

Suven Pharmaceuticals Limited Goodwill for the year ending March 31, 2024: USD 7.22 M

Suven Pharmaceuticals Limited Goodwill is USD 7.22 M for the year ending March 31, 2024, a -1.46% change year over year. Goodwill is the value attributed to intangible assets, such as brand reputation or customer relationships, acquired in a business combination.

Suven Pharmaceuticals Limited Goodwill for the year ending March 31, 2023 was USD 7.33 M, a 0.00% change year over year.
Suven Pharmaceuticals Limited Goodwill for the year ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
Suven Pharmaceuticals Limited Goodwill for the year ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
Suven Pharmaceuticals Limited Goodwill for the year ending March 31, 2020 was USD 0.00, a 0.00% change year over year.

Key data

Date	Goodwill	Total Assets	Current Liabilities	Total Non-Current Liabilities

NSE: SUVENPHAR.NS

Suven Pharmaceuticals Limited

CEO	Dr. Sudhir Kumar Singh Ph.D.
IPO Date	March 9, 2020
Location	India
Headquarters	# 8-2-334, SDE Serene Chambers
Employees	1,193
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cosmetics Drugstores & Retail Pharmacies Personal Care Petrochemicals Pharmaceuticals Plastics

Description

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was incorporated in 2018 and is headquartered in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.

Key trends

Past 5 years